Did you know?
In Indonesia, 46.9% of hospitalised diabetic foot infection patients face amputation. Nearly half, in a country where 1 in 10 adults lives with diabetes.
Recce's Phase 3 clinical trial for diabetic foot infections is currently underway in Indonesia.
#DFI #Diabetes #Indonesia #InfectiousDiseases #AMR
Health Check by Tim Boreham: EMVision aces its RFDS trial, @Neurizon_ltd
expands its ALS study, @cynatastemcells expects two late-stage readouts in June and @ReccePharma signs a 10-year Middle Eastern licensing deal.
🔗 https://t.co/kwXyr5cuho
$EMV $NUZ $CYP $RCE
.@ReccePharma has inked a non-binding term sheet with a leading Middle Eastern pharmaceutical company for a proposed 10-year exclusive licensing deal for its anti-infective R327 Topical Gel (R327G) to treat diabetic foot infections. #ASX $RCE https://t.co/4uhNOq1Baz
#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE), advises that it has entered into a non-binding term sheet with a leading Middle Eastern pharmaceutical company (Licensee) for an exclusive licensing arrangement covering the commercial sales and distribution of the Company’s proprietary R327 Topical Gel (R327G) for the treatment of Diabetic Foot Infections (DFIs) across the Middle East and North Africa (MENA) region.
Read the full ann here: https://t.co/xX0vpHebAF
Pain is your body's early warning system.
Diabetic neuropathy gradually removes it. Nerve damage means wounds can form, worsen, and become infected with no signal that anything is happening.
By the time it's visible, it's often already advanced.
#DiabeticNeuropathy#DFI #Diabetes #DiabeticFoot #InfectiousDiseases
Diabetic foot infection affects more than the wound.
It is associated with reduced mobility, loss of independence, and significant emotional and financial burden on patients and their families.
The clinical impact is only part of the picture. Recognising infection early remains one of the most important factors in improving long-term outcomes.
#STOPandTURN #DiabeticFootInfection #DiabetesCare #WoundCare #InfectionAwareness #DFI
A woman who found out she was diabetic at seven years old has told how stepping on a dog biscuit led to her right leg being amputated.
Read the full article here: https://t.co/XFps8cH5Lc
You're in hospital. The antibiotic isn't working. It gets changed. Still nothing.
A small group of bacteria survived, the resistant ones. With the competition gone, they took over.
This is antimicrobial resistance. It happens to real patients, right now.
#AMR #AntibioticResistance #Superbugs #InfectiousDiseases
$RCE Recce Pharmaceuticals advances US Army burn wound program and Indonesia Phase 3 trial in March quarter https://t.co/7XVSWaQNKl @ReccePharma#RCE#RECEF#ASX#ASXNews
There's no passive option when infection appears in a diabetic foot ulcer.
Delays allow infection to progress. Risk increases. Options narrow.
Doing nothing is still a decision.
#STOPandTURN#DiabeticFootInfection#WoundCare#AMR#DFI
Indonesian authorities have completed a comprehensive routine regulatory inspection of @ReccePharma's Phase III trial site.
#ASX#health $RCE
https://t.co/84ZApF2E8i
#ASX Ann - Recce Pharmaceuticals Ltd (ASX:RCE), is pleased to announce that the Indonesian National Agency of Drug and Food Control (Badan POM or BPOM) has successfully completed a comprehensive routine regulatory inspection of a Phase 3 (Trial Name: R327-G301) clinical trial site in Indonesia.
Read the full ann here: https://t.co/xX0vpHebAF
What defines Recce’s investment story?
A unique mechanism targeting ATP production. Late-stage clinical progress. A growing role in addressing antimicrobial resistance.
via @Edison_Inv_Res
https://t.co/kp7jWihoO4
Nearly a century after penicillin ushered in the first antibiotic revolution, @ReccePharma $RCE is aiming to help deliver the next class of antibiotics to tackle drug-resistant superbugs.
https://t.co/gVDhnBLcO5
In diabetic foot infections, infection is more than a clinical event.
It represents a moment where direction can shift.
Earlier recognition and timely management may influence outcomes.
As infection progresses, options can become more limited.
#DiabeticFoot#DFI #InfectionAwareness #AMR #WoundCare #Healthcare
Stockhead TV host Tylah Tully sits down with @ReccePharma $RCE managing director and CEO James Graham as he outlines how the company’s synthetic anti-infective platform represents the first new class of antibiotics in over 40 years.
https://t.co/s9JkaeuKlw